Clinical Trial Update: Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial comparing trastuzumab deruxtecan to standard neoadjuvant therapy for HER2-positive breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: Karolinska University Hospital | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING